PMID- 20724749
OWN - NLM
STAT- MEDLINE
DCOM- 20110113
LR  - 20211020
IS  - 1943-7811 (Electronic)
IS  - 1525-1578 (Print)
IS  - 1525-1578 (Linking)
VI  - 12
IP  - 5
DP  - 2010 Sep
TI  - Array comparative genomic hybridization detects chromosomal abnormalities in 
      hematological cancers that are not detected by conventional cytogenetics.
PG  - 670-9
LID - 10.2353/jmoldx.2010.090192 [doi]
AB  - Application of array comparative genomic hybridization (aCGH) has allowed an 
      unprecedented high-resolution analysis of cancer genomes. We developed a custom 
      genome-wide oligonucleotide microarray interrogating 493 genes involved in 
      hematological disorders. We analyzed 55 patients with hematological neoplasms by 
      using this microarray. In 33 patients with apparent normal conventional 
      cytogenetic analysis, aneuploidy or isochromosomes were detected in 12% (4 of 33) 
      of the patients by aCGH. The chromosomal changes included trisomy of chromosomes 
      10, 14, and 15, tetrasomy 11, and isochromosome 17q. In 17 patients with chronic 
      lymphocytic leukemia who were initially investigated by using a panel of standard 
      fluorescence in situ hybridization probes, additional copy number changes that 
      were not interrogated by the fluorescence in situ hybridization (FISH) panel were 
      detected in 47% (8 of 17) of the patients by aCGH. Important copy number changes 
      included gain on 2p16 involving REL and BCL11A genes, rearrangements of 
      chromosomes 8 and 15, and trisomy of chromosomes 19 and 22. In five patients with 
      known abnormal karyotypes, aCGH identified the origin of two marker chromosomes 
      and detected microdeletions at five breakpoints involved in three apparent 
      balanced translocations. Our results suggest that a subset of potentially 
      significant genomic alterations is missed by the currently available cytogenetic 
      techniques. This pilot study clearly demonstrates high sensitivity of 
      oligonucleotide aCGH for potential use in diagnosis and follow-up in patients 
      with hematological neoplasms.
FAU - Shao, Lina
AU  - Shao L
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      Texas 77021-2039, USA.
FAU - Kang, Sung-Hae L
AU  - Kang SH
FAU - Li, Jian
AU  - Li J
FAU - Hixson, Patricia
AU  - Hixson P
FAU - Taylor, Jesalyn
AU  - Taylor J
FAU - Yatsenko, Svetlana A
AU  - Yatsenko SA
FAU - Shaw, Chad A
AU  - Shaw CA
FAU - Milosavljevic, Aleksandar
AU  - Milosavljevic A
FAU - Chang, Chung-Che
AU  - Chang CC
FAU - Cheung, Sau Wai
AU  - Cheung SW
FAU - Patel, Ankita
AU  - Patel A
LA  - eng
PT  - Journal Article
DEP - 20100819
PL  - United States
TA  - J Mol Diagn
JT  - The Journal of molecular diagnostics : JMD
JID - 100893612
SB  - IM
MH  - *Chromosome Aberrations
MH  - Hematologic Neoplasms/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Nucleic Acid Hybridization
MH  - Oligonucleotide Array Sequence Analysis
PMC - PMC2928432
EDAT- 2010/08/21 06:00
MHDA- 2011/01/14 06:00
PMCR- 2011/09/01
CRDT- 2010/08/21 06:00
PHST- 2010/08/21 06:00 [entrez]
PHST- 2010/08/21 06:00 [pubmed]
PHST- 2011/01/14 06:00 [medline]
PHST- 2011/09/01 00:00 [pmc-release]
AID - S1525-1578(10)60112-2 [pii]
AID - JMDI60112 [pii]
AID - 10.2353/jmoldx.2010.090192 [doi]
PST - ppublish
SO  - J Mol Diagn. 2010 Sep;12(5):670-9. doi: 10.2353/jmoldx.2010.090192. Epub 2010 Aug 
      19.